Skip to Main Content

Faculty Directory

Back to
Faculty Directory
Jay Horton, M.D.

Jay Horton, M.D.

Titles and Appointments

Professor & Director

Endowed Title
Center for Human Nutrition Director's Endowed Chair; Distinguished University Chair in Human Nutrition; Scott Grundy Director's Chair
School
Medical School
Department
Center for Human Nutrition | Internal Medicine | Molecular Genetics
Graduate Programs
Cell and Molecular Biology

You have reached the Academic Profile.

For more information on the doctor and patient care, please visit the clinical profile.

  • Biography

    Download Curriculum Vitae

    Jay D. Horton obtained his B.S. and M.D. degrees from the University of Iowa in 1984 and 1988, respectively. He completed his internal medicine residency (1988-1991) and gastroenterology fellowship (1991-1994) at UT Southwestern Medical Center. During his gastroenterology fellowship he studied metabolic regulators of bile acid and cholesterol homeostasis in animals. Following the gastroenterology fellowship, he completed a Howard Hughes post doctoral fellowship in the Department of Molecular Genetics at UT Southwestern Medical Center. The studies in this fellowship focused on the transcriptional regulation of cholesterol and fatty acid synthesis.

    In clinical digestive diseases, Dr. Horton has an interest in conditions that lead to steatosis and obesity. Currently the laboratory is investigating molecular mediators of steatosis using various mouse models. Investigations from the laboratory have revealed how the primary transcriptional regulators of cholesterol metabolism (sterol regulatory element-binding proteins) are also key regulators of fatty acid synthesis in liver.

    A major focus of the laboratory is to determine how these transcriptional regulators contribute to the development of steatosis in various disease processes such as diabetes, obesity, and beta-oxidation defects.

    A second area of investigation centers on determining the function of PCSK9, a protein that is involved in determining plasma LDL cholesterol levels through its ability to post-transcriptionally regulate the expression of the LDL receptor in liver.